Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Summary

This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer.

Timeline

Start

2005-12

Primary completion

2008-10

Completion

2010-08

Drugs

Indications